drugset / Trial / NCT06068465
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Timeline
- Start
- 2024-09-27
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |